UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdiction o ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Securities Dae Gon Ha - Stifel Liisa Bayko ...

l ■ l IIII Immuno-oncology Autoimmune diseases In Vivo Leader: First to Demonstrate Systemic CRISPR Gene Editing in Humans 12 * Lead development and commercial party; ** Rights to certain in vivo targets; *** Milestones & royalties only AATD: alpha-1 antitrypsin deficiency; CAR-T: chimeric Antigen Receptor T Cells; HSC: hematopoietic stem cells; OSC: ocular stem cells; TCR: T cell receptor Capable of delivering to multiple tissue types for various therapeutic applications | --- | --- | --- | --- | |-------| ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdiction ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Maury Raycroft - Jeffries Greg Harrison - Bank of America Swapnil Malekar - Piper Sandler Terence Flynn - Morgan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 40 Erie Street, Suite 130 (State or other jurisdiction of incorporation or organization) Cambridge, Massachusetts 02139 (Address o ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview NOVEMBER 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's belief ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2022 Results Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdict ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview SEPTEMBER 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's belie ...